AlloMap, a noninvasive FDA-cleared test, has been on the market in the US since January 2005.
It provides transplant physicians with a tool to aid in the determination of the probability of acute cellular rejection for post-cardiac transplant patient management.
XDx president and CEO Pierre Cassigneul said gaining a CE mark is a major step in making AlloMap available to European practitioners and patients.
California-based XDx is a molecular diagnostics company focused on the discovery, development and commercialization of noninvasive gene expression-based tests for the monitoring of transplant rejection and autoimmune diseases.
